drugset / Trial / NCT02802345

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

NCT02802345

Phase 3 Completed 274 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.

Timeline

Start
2016-06-30
Primary completion
2017-12-19
Completion
2018-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 150 mg Oral
Comparator Sildenafil Unknown 20 mg Oral